Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.mehy.2020.109947 http://scihub22266oqcxt.onion/10.1016/j.mehy.2020.109947 32505070!7833589!32505070     free     free     free       Med+Hypotheses 2020 ; 144 (ä): 109947 Nephropedia Template TP {{tp|p=32505070|t=2020. Nebulized Lidocaine in COVID-19, An Hypothesis |pdf=|usr=}}{{32505070}} gab.com Text Nebulized Lidocaine in COVID-19, An Hypothesis JO: Med Hypotheses http://www.kidney.de/pget.php?&tw=1&pmid=32505070 #FOAvip Coronavirus Diseases-2019 (COVID-19) has caused a large global outbreak and has been declared as a pandemic by the World Health Organization (WHO). It has been proposed that COVID-19-related hyperinflammation and dysregulated immune response might play a critical role in developing a cytokine storm which usually progresses to a life-threatening acute lung injury or acute respiratory distress syndrome in infected individuals. Lidocaine, a local analgesic and anti-arrhythmic, is known for its anti-inflammatory actions and has been used to reduce cough and improve respiratory symptoms in severe asthmatic patients. It has a demonstrated safety profile. It is proposed that nebulized lidocaine might be beneficial in reducing cytokines, protecting patients' lungs and improving outcomes in COVID-19 patients when administered via inhalation as an adjunctive treatment for severe respiratory symptoms in patients fighting the novel Coronavirus. Additional investigation is warranted. Twit Text FOAVip Nebulized Lidocaine in COVID-19, An Hypothesis ????Med Hypotheses http://www.kidney.de/pget.php?&tw=1&pmid=32505070 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32505070 #FOAvip English Wikipedia <ref>{{Cite pmid|32505070}}</ref> Nebulized Lidocaine in COVID-19, An Hypothesis #MMPMID32505070 Ali ZA; El-Mallakh RS Med Hypotheses 2020[Nov]; 144 (ä): 109947 PMID32505070show ga Coronavirus Diseases-2019 (COVID-19) has caused a large global outbreak and has been declared as a pandemic by the World Health Organization (WHO). It has been proposed that COVID-19-related hyperinflammation and dysregulated immune response might play a critical role in developing a cytokine storm which usually progresses to a life-threatening acute lung injury or acute respiratory distress syndrome in infected individuals. Lidocaine, a local analgesic and anti-arrhythmic, is known for its anti-inflammatory actions and has been used to reduce cough and improve respiratory symptoms in severe asthmatic patients. It has a demonstrated safety profile. It is proposed that nebulized lidocaine might be beneficial in reducing cytokines, protecting patients' lungs and improving outcomes in COVID-19 patients when administered via inhalation as an adjunctive treatment for severe respiratory symptoms in patients fighting the novel Coronavirus. Additional investigation is warranted. |*COVID-19 Drug Treatment[MESH] |*Models, Biological[MESH] |Administration, Inhalation[MESH] |Anesthetics, Local/administration & dosage[MESH] |Anti-Inflammatory Agents/administration & dosage[MESH] |COVID-19/complications/immunology[MESH] |Cytokine Release Syndrome/drug therapy/etiology/immunology[MESH] |Humans[MESH] |Lidocaine/*administration & dosage[MESH] |Nebulizers and Vaporizers[MESH] |Pandemics[MESH]Nebulized Lidocaine in COVID-19, An Hypothesis (epmc).pdf DeepDyve Pubget Overpricing